

House Research Act Summary

CHAPTER: 182

SESSION: 2016 Regular Session

TOPIC: Controlled Substance Schedule Updates

Analyst: Jeff Diebel

Date: May 24, 2016

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: www.house.mn/hrd/.

This act updates the schedules of controlled substances contained in chapter 152. Minnesota law requires the Executive Director of the Board of Pharmacy to recommend to the legislature updates to the statutory controlled substance schedules so that the statutory schedules match the schedules maintained by the Board. The act adds fourteen synthetic drugs to Schedule I. These drugs are either cannabinoids, hallucinogens, stimulants, or CNS depressants. The Board of Pharmacy has concluded that each of the drugs can be abused, are potentially addictive, and have no approved medical uses, which are the criteria for placing a drug on schedule I. The BCA and local law enforcement agencies have notified the Board of Pharmacy that these drugs have been confiscated in Minnesota.

This act also adds the drug eluxadoline to Schedule IV. Eluxadoline is a FDA-approved drug that is used for the treatment of irritable bowel syndrome. Upon its approval, it was placed in the federal Schedule IV.